[
    [
        {
            "time": "2023-10-01",
            "original_text": "负面！健帆生物：董事兼副总经理唐先敏等人计划减持不超过877万股 拟减持股份",
            "features": {
                "keywords": [
                    "健帆生物",
                    "董事",
                    "副总经理",
                    "减持",
                    "877万股"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "负面！健帆生物：董事兼副总经理唐先敏等人计划减持不超过877万股 拟减持股份",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "健帆生物(300529.SZ)：部分董监高拟合计减持不超过1.1%的股份 拟减持股份",
            "features": {
                "keywords": [
                    "健帆生物",
                    "董监高",
                    "减持",
                    "1.1%"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "健帆生物(300529.SZ)：部分董监高拟合计减持不超过1.1%的股份 拟减持股份",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "健帆生物：6名董监高拟合计减持不超过1.1% 减持股份",
            "features": {
                "keywords": [
                    "健帆生物",
                    "董监高",
                    "减持",
                    "1.1%"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "健帆生物：6名董监高拟合计减持不超过1.1% 减持股份",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "医药生物行业2020年中期策略：拥抱疫情后周期投资机会 重点关注医药新基建和医药大消费",
            "features": {
                "keywords": [
                    "医药生物",
                    "疫情后周期",
                    "投资机会",
                    "医药新基建",
                    "医药大消费"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药生物行业2020年中期策略：拥抱疫情后周期投资机会 重点关注医药新基建和医药大消费",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 4,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "医药行业2020年中期投资策略：坚持高景气赛道+龙头战略",
            "features": {
                "keywords": [
                    "医药行业",
                    "高景气赛道",
                    "龙头战略"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药行业2020年中期投资策略：坚持高景气赛道+龙头战略",
                "Correlation": 4,
                "Sentiment": 8,
                "Importance": 6,
                "Impact": 4,
                "Duration": 7,
                "Entity_Density": 2,
                "Market_Scope": 10,
                "Time_Proximity": 4,
                "Headline_Structure": 8,
                "Source_Recency": 3
            }
        }
    ]
]